We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radiotherapy and gemcitabine--docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
- Authors
Jun Ah Lee; Eun Kyung Paik; Juhee Seo; Dong Ho Kim; Jung Sub Lim; Ji Young Yoo; Mi-Sook Kim
- Abstract
Objective: Few reports have described the treatment outcome of osteosarcoma using radiotherapy. We evaluated the efficacy of radiotherapy and gemcitabine and docetaxel chemotherapy for patients with unresectable recurrent or refractory osteosarcoma. Methods: Data from six patients (five male, one female) who received radiotherapy and gemcitabine and docetaxel chemotherapy at the Korea Cancer Center Hospital were retrospectively reviewed. Tumor response was evaluated according to metabolic changes using 18F-fluorodeoxy-D-glucosepositron emission tomography. Results: The median age of the patients was 15.0 years (range, 14.0-15.8 years). Two patients had single bone lesions, and four had multiple metastatic bone lesions. Patients received a median 3.5 courses of gemcitabine and docetaxel chemotherapy (range, 2-6 courses). The median dose of radiotherapy was 50.0 Gy (range, 46-84 Gy). There were two complete metabolic responses and one partial metabolic response. The objective response rate was 50.0% (3/6). Responses were maintained for 4.6, 6.1 and 13.7 months, respectively. Patients were followed up for a median of 5.8 months (range, 2.7-84.6 months), and the median progression-free survival after this treatment was 3.6 months (range, 1.1-13.7 months). At the time of analysis, two patients were alive, one was lost to follow-up and three had died. Conclusion: Radiotherapy with gemcitabine and docetaxel chemotherapy showed some improvement in cases of refractory tumors or multiple bone metastases. Further studies are needed to investigate the efficacy of newer radiotherapy modalities, as well as to identify new radiosensitizing chemotherapy regimens.
- Publication
Japanese Journal of Clinical Oncology, 2016, Vol 46, Issue 2, p138
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyv171